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The aim of this study was to find out whether human immunodeficiency virus (HIV)-infection and 
antiretroviral drugs influence multidrug-resistant (MDR)-tuberculosis (TB) treatment outcomes. The 
study compares MDR-TB treatment outcomes between HIV-positive and HIV-negative patients. It 
involved patients admitted for treatment of MDR-TB between 1 January 2004 and 31 December 2006. 
From 363 patients selected, 268 (177 males and 91 females) had MDR-TB and 95 patients (59 males and 
36 females) were co-infected with HIV. Children in the HIV-negative group were 41 and 7 in the HIV-
positive group. The HIV-infection was treated with Stavudine, Lamivudine and Efavirenz in 54 patients. 
Kanamycin, Ethionamide, Ofloxacin, Terizidone, Pyrazinamide and Ethambutol were used for MDR-TB 
treatment. In HIV-negative and HIV-positive patients MDR-TB treatment outcomes  were, respectively as 
follows: 37 and 35% cure, 9 and 5% treatment failure, 20 and 25% lost to follow up, 11 and 17% 
mortality, 19 and 13% treatment completed, 6 and 5% transfer-out. The cure rate was 100% in children. 
In HIV-positive patients, MDR-TB cure rate was 35% in patients on ARVs and 34% in patients not 
receiving ARVs. The difference between these cure rates is not statistically significant (p-value = 0.79). 
The median (range) duration of ART before the start of MDR-TB treatment was 10.5 (1 to 60) months and 
did not influence MDR-TB treatment outcomes. In children, the full treatment was supervised in 
hospital. This could explain the 100% cure rate. Adults’ treatment was supervised in hospital only 
during the intensive phase then followed up as out patients over 18 months. According to the results of 
this study, HIV-infection and antiretroviral therapy did not influence MDR-TB treatment outcomes.  
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antiretroviral agents. 
 
 
INTRODUCTION 
 
According to the National Department of Health (DOH) 
(Department of Health, Republic of South Africa 2011), 
South Africa is the world’s third highest burden 
tuberculosis (TB) country and ranks the 5th highest with 
regards to drug-resistant tuberculosis (DR-TB). 
Furthermore, the numbers of multiple drug-resistant 
tuberculosis (MDR-TB) and extensively drug-resistant 
tuberculosis (XDR-TB) patients have increased due to 
the concurrent human immunodeficiency virus (HIV) 
epidemic and inadequate management of TB. MDR-TB is 
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defined as resistance of Mycobacterium tuberculosis (M. 
tuberculosis) against, at least, isoniazid and rifampicin 
(Department of Health, 2013). XDR-TB represents a 
progression from MDR-TB to further include resistance to 
second line anti-TB drugs, including any fluoroquinolone 
and at least one of three second line injectables, namely, 
Kanamycin, Amikacin or Capreomycin (Department of 
Health, 2013). From 2004 to 2009, there has been a 
steady increase in the number of cases. In all nine 
provinces, the total number of MDR-TB and XDR-TB 
cases was 45196 and 3128, respectively. The most 
affected provinces were KwaZulu-Natal with 11393 
(25.2%) MDR-TB cases and the Western Cape with 
10947 (24.2%) MDR-TB cases notified. They were 
followed by the Eastern Cape and Gauteng Province with 
7993 (17.6%) and 6200 (13.7%) cases notified, 
respectively. Out of 3128 XDR-TB cases, KwaZulu-Natal 
notified 1499 (47.9%), the Western Cape notified 342 
(10.9%), the Eastern Cape 808 (25.8%) and the Gauteng 
Province 208 (6.6%) (Department of Health, Republic of 
South Africa 2011). South Africa had the highest reported 
number of MDR-TB and XDR-TB cases in Africa in 2007 
(World Health Organization, 2009). 
The increase in notified TB cases has been largely 
attributed to the concurrent HIV epidemic. An estimated 
73% of the reported TB cases in South Africa are among 
people living with HIV/AIDS (World Health Organization 
2009). TB is the leading reported cause of death by 
natural causes (Statistics South Africa, 2014). The 
emergence of drug resistance, developing among many 
other factors, such as poor adherence to anti-TB 
treatment, has become a serious challenge. Patients with 
drug resistant TB are more difficult to treat and also have 
poorer outcomes (Holtz et al., 2006; Nathanson et al., 
2006; Kim et al., 2010; Shean et al., 2008; Pepper et al., 
2009). 
In South Africa, MDR-TB is treated in referral hospitals. 
In the Province of Western Cape, there are  four MDR-TB 
hospitals. These are Brooklyn Chest Hospital and DP 
Marais Hospital in the Cape Metropole region, Harry 
Comay Hospital in the Eden and Central Karoo region 
and Brewelskloof Hospital (BKH) in the Cape Winelands 
and the Overberg. According to the national DOH, MDR-
TB cure rate is estimated around 30 to 50% (World 
Health Organization, 2009). There is limited data about 
MDR-TB treatment outcomes and the prevalence of HIV 
among MDR-TB patients (Sanchez-Padila et al., 2012). 
The influence of HIV and the impact of antiretroviral 
(ARV) drugs and anti-TB drugs on MDR-TB treatment 
outcomes need to be investigated.  
Therefore, the objective of this study was to assess the 
influence of HIV infection and antiretroviral drugs on 
MDR-TB treatment outcomes. 
 
 
METHODOLOGY 
 
The   study  was  conducted  at  BKH  and  is  a  retrospective  case 
 
 
 
 
control study comparing the treatment outcomes of MDR-TB 
patients co-infected with HIV (experimental group) and patients 
infected with MDR-TB (control group). BKH serves approximately 
1.3 million people and receives approximately 100 referrals per 
month.  
Patients were included in the study only if they complied with all 
of the following criteria: (1) those who are MDR-TB sensitive to 
second line anti-TB drugs with and without HIV infection,  (2)  those 
who completed the treatment between 1 January 2006 and 31 
December 2008. 
The drugs used to treat MDR-TB patients at BKH during the 
study period include Ethambutol (EMB), Pyrazinamide (PZA), 
Kanamycin (KAN), Ofloxacin (OFLOX), Ethionamide (ETH) and 
Cycloserine/Terizodone (CYC/TER). The dosage of each drug was 
determined according to the patient’s body weight. 
The data was collected from TB registers and clinical records and 
entered into a database using Excel (Microsoft Office 2003). The 
following information was captured: the patient’s demographics, his 
or her age, his or her HIV status, his or her immunological profile, 
his or her history of previous TB treatment and HIV treatment, and 
his or her MDR-TB treatment outcomes. The following 2011 World 
Health Organization (WHO) MDR-TB treatment outcomes were 
used: cure, treatment completed, failure, default, transfer/moved 
out, and death. “Cure” was defined as when MDR-TB patient, who 
has completed treatment according to the guidelines, has at least 
five consecutive negative cultures from samples collected at least 
30 days apart in the final 12 months of treatment. “Treatment 
completed” refers to a patient who has completed the treatment, but 
does not yet meet the criteria to be classified as cured or failure. 
“Treatment failure” is a situation in which two or more of the five 
cultures recorded in the final 12 months of therapy are positive, or if 
any one of the final three cultures is positive. “Default” was used for 
a patient whose treatment is interrupted for two consecutive months 
or more. “Transferred”/”moved out” mean that a patient is 
transferred or moved to another facility to continue treatment.  
“Death” applies to a patient who, has died for any reason(s) during 
the course of treatment.  
All quantitative variables were analyzed using medians as a 
measure of location, and range as measure of spread.  Nominal 
variables were descriptively analyzed using frequency distributions 
indicating the absolute and relative frequencies. The primary 
outcome was to determine whether there is a difference in “cure”, 
“treatment completed”, “treatment failure”, “default”, “transfer out” 
and “death” rates between the HIV (+) and HIV (-) groups.  For this 
comparison, the Pearson’s chi-square test was used. The degree of 
freedom is equal to one. With one degree of freedom, the value that 
must be exceeded to establish significance at the 0.05 level is 3.84.  
Ethical approval for the study was obtained from the Ethics 
Committee of the University of the Western Cape (Ref: 2009/3/18). 
The permission to conduct the study was granted by the Western 
Cape DOH. The study was done in accordance with the Helsinki 
Declaration and confidentiality was observed.  
 
 
RESULTS 
 
Patient demographics  
 
As indicated in Tables 1 and 2, 363 patients started 
MDR-TB treatment between the 1st of January 2004 and 
the 31st of December 2006. They include 268 (74%) 
MDR-TB patients involving 177 (66%) males and 91 
(34%) females, plus 95 (26%) MDR-TB patients who 
were co-infected with HIV of which 51 (54%) were males 
and 44 (46%) were females. The number of patients
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Table 1. Number of patients per year. 
 
Year 
Patients with MDR-TB, Nb (%)  Patients with MDR-TB + HIV, Nb (%) 
Total 
Male Female Total (M+F)  Male Female Total (M+F) 
2006 47 (70) 20 (30) 67 (25)  14 (58) 10 (42) 24 (25) 91 
2007 63 (67) 31 (33) 94 (35)  20 (53) 18 (47) 38 (40) 132 
2008 67 (63) 40 (37) 107 (40)  17 (52) 16 (48) 33 (35) 140 
Total 177 (66) 91 (34) 268 (74%)  51 (54) 44 (46) 95 (26%) 363 
 
 
 
Table 2. Age distribution. 
 
Age 
Patients with MDR-TB, Nb (%)  Patients with MDR-TB & HIV, Nb (%) 
Total 
Male Female Total  Male Female Total 
0-5 7 (35) 13 (65) 20 (8)  0 0 0 20 
6-9 3 (50) 3 (50) 6 (2)  0 1 (100) 1 (1) 7 
10-14 10 (67) 5 (33) 15 (6)  3 (50) 3 (50) 6 (6) 21 
15-24 22 (69) 10 (31) 32 (12)  5 (45) 6 (41) 11 (12) 43 
25-34 44 (66) 23 (34) 67 (25)  13 (59) 99 (41) 22 (23) 89 
35-44 48 (66) 25 (34) 73 (27)  18 (51) 17 (49) 35 (37) 108 
45-54 30 (79) 8 (21) 38 (14)  6 (55) 5 (45) 11 (12) 49 
≥55 13 (76) 4 (24) 17 (6)  6 (66) 3 (33) 9 (9) 26 
Total 177 (66) 91 (34) 268  51 (54) 44 (46) 95 363 
Total (M+F) 268 (74) 
 
 95 (26) - 363 
 
 
 
infected with MDR-TB increased with time in HIV-
negative and HIV-positive patients. The number of 
children in the HIV-negative group was 41 (15.2%) and 7 
(7.4%) in the HIV-positive group. The prevalence of 
MDR-TB was higher between the age of 15 and 55 years. 
 
 
MDR-TB treatment outcomes 
 
As shown in Table 3, MDR-TB cure rate is 37% in HIV-
negative patients and 35% in HIV-positive patients. There 
is no significant difference (p = 0.4451) in both cure rates. 
The cure rate was 100% in children. 
The other MDR-TB treatment outcome rates in HIV-
negative and HIV-positive patients are 9 and 5% failure, 
20 and 25% default, 11 and 17% death, 19 and 13% 
treatment completed, 6 and 5% transfer-out, respectively. 
The differences between all these outcomes were not 
statistically significant.  
 
 
Influence of antiretroviral therapy on the cure rate 
 
Out of 95 HIV (+) patients, 54 (57%) patients were 
treated with Stavudine, Lamivudine and Efavirenz. The 
median (range) duration of antiretroviral therapy (ART) 
before MDR-TB treatment was 10.5 (1-60) months.  
MDR-TB cure rate is 35% in the group of HIV (+) positive 
patients on ARVs and 34% in the group not receiving 
ARVs. The difference between both cure rates is not 
statistically significant (p-value = 0.79) (Table 4). 
All adult patients infected with HIV received 
Cotrimoxazole (Trimethoprim 80 mg/Sulfamethoxazole 
400 mg) 2 tablets daily for PJP prophylaxis regardless of 
CD4 cell count. 
 
 
Anti-TB drugs received 
 
In this study, 336 patients ≥14 years old received PZA, 
EMB, KAN, OFLOX, ETH and CYC/TER for MDR-TB 
treatment. The other 27 patients, <14 years old, were 
treated as indicated in Figure 1.  
 
 
Duration of antiretroviral therapy (ART) before the 
start of MDR-TB treatment  
 
The median duration of ART before the start of MDR-TB 
treatment is 10.5 months. It ranges from 1 to 60 months. 
Viral load or CD4 cell count results were not available. 
 
 
DISCUSSION  
 
This study compares MDR-TB treatment outcomes 
between 95 HIV-positive and 268 HIV-negative patients 
admitted at BKH between January 2004 and December
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Table 3. MDR–TB treatment outcomes. 
 
Treatment (Rx) outcomes 
MDR-TB patients, Nb (%)  HIV (+) MDR-TB patients, Nb (%)  HIV (+) & (-) 
Male Female Total  Male Female Total  Total, Nb (%) 
Cure 60 (34) 38 (43) 98 (37)  20 (34) 13 (36) 33 (35)  131 (36) 
Failures 19 (11) 5 (6) 24 (9)  4 (9) 1 (3) 5 (5)  29 (8) 
Defaulted 34 (19) 18 (20) 52 (20)  14 (24) 10 (28) 24 (25)  76 (21) 
Died 25 (14) 4 (4) 29 (11)  10 (17) 6 (17) 16 (17)  45 (12) 
Rx completed 26 (15) 23 (26) 49 (19)  8 (14) 4 (11) 12 (13)  61 (17) 
Transferred out 13 (7) 3 (3) 16 (6)  3 (5) 2 (6) 5 (5)  21 (6) 
Total 177 (66) 91 (34) 268 (74)  59 (62) 36 (38) 95 (26)  363 
 
 
 
Table 4. Influence of antiretroviral therapy on MDR-TB cure rate.  
 
Variable HIV (+) patients without ARVs (%) HIV (+) patients on ARVs (%) Total 
Not cured 27 (66) 35 (65) 62 (65) 
Cured 14 (34) 19 (35) 33 (35) 
Total 41 (43) 54 (57) 95 
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Figure 1. Number of paediatric patients per anti-TB drug. 
 
 
 
2006. In both groups, the prevalence of MDR-TB has 
been significantly increasing during the study period. 
MDR-TB prevalence is higher in males than females, 
regardless of their HIV status and affects more of the 
working class population (25 to 55 years). Statistics from 
the United States of America, show that TB is a disease 
that mainly affects those who are 55 years of age and 
older or of the  immuno-compromised  people  (Kumar  et 
al., 2007).  
The total cure rate found in this study (36%) is higher 
than that found in the same hospital in 2003 (29.4%), 
2004 (31.3%) and in 2005 (20%) (Theron, 2003-2005). 
These findings are consistent with MDR–TB cure rates 
reported at national level (30 to 50%) in patients without 
HIV infection in South Africa (Department of Health 
2013). This   study   does   not    show    any     significant 
 
 
 
 
difference (p = 0.4451) in MDR-TB cure rate between 
HIV-negative (37%) and in HIV-positive patients (35%).    
The increased percentage of patients (17% HIV-
positive and negative) who have completed the 
treatment, but not yet meet the criteria to be classified as 
cured, could be a sign of a lack of therapeutic counseling 
of patients, poor treatment adherence support and weak 
treatment regimens. 
There is no significant difference (p = 0.1779) between 
the treatment failure rate in MDR-TB patients (9%) and in 
patients co-infected with MDR-TB and HIV (5%). The 
failure rates found in this study are statistically not 
different to those reported in the same hospital in 2003 
(5.9%), 2004 (9.0%) and 2005 (4.7%) (Theron, 2003-
2005). 
The default rate in MDR-TB patients (20%) is 
statistically similar (p = 0.4264) to the one found in MDR-
TB patients co-infected with HIV (25%). However, these 
rates are unacceptably high and the risk factors 
associated with them need to be investigated. In a study 
conducted in South Africa in 2002 (Finlay et al., 2012), it 
was found that significant risk factors associated with 
default rate include poor health workers support, 
changing residence during TB treatment, not receiving 
adequate counseling about treatment, feeling ashamed to 
have TB and seeking care from a traditional healer, 
stopping treatment because the patient felt better, and 
having a previous history of TB treatment non-adherence. 
These factors may have contributed to poor treatment 
outcomes in this study as well. 
The relatively low percentage of patients who moved to 
another facility to continue treatment (6% in MDR-TB 
patient group and 5% in patients co-infected with HIV) 
can be seen as a sign of patients’ satisfaction about 
health services at BKH.   
The death rate in this study was 11% in MDR-TB 
patients and 17% in patients co-infected with HIV. No 
significant statistical difference (p = 0.1837) was found 
between both groups. At BKH, in 2003, 2004 and 2005, 
the death rate was 5.9, 9.0 and 24.7%, respectively 
(Theron, 2003-2005).  
 
 
Impact of antiretroviral therapy on MDR-TB cure rate 
 
When some HIV (+) patients were involved in the study, 
they had been on ART for 10.5 (1 to 60) months. The 
duration of the exposure is long enough to show an 
interaction between ARVs and anti-TB drugs, if any. The 
number of studies demonstrating interactions between 
second-line anti-TB drugs that are used in MDR-TB 
treatment regimens and ARVS are limited, although the 
potential for adverse events due to drug interactions is 
considerable.  
It has been demonstrated in this study that HIV 
infection does not influence MDR-TB treatment 
outcomes. With the small number of patients involved in 
this study, assessment could not be done for whether co- 
Mugabo et al.          879 
 
 
 
infection with HIV exposes MDR-TB patients to more 
drug toxicities and drug-drug interactions as it was 
demonstrated  by Meintjes (2014).  
Furthermore, since there is no difference between 
treatment outcomes within the group of HIV (+) MDR-TB 
patients taking ARVs and the group of HIV (+) MDR-TB 
patients not receiving ARVs, it  can be stated  that ARV 
therapy does not influence MDR-TB treatment. 
 
 
Conclusion 
 
The aim of this retrospective study was to investigate the 
effect of HIV-infection and ART on MDR-TB treatment 
outcomes. It was found that neither HIV infection, nor 
ARVs have an impact on the MDR-TB treatment 
outcomes at BKH. Furthermore, no drug interactions 
were found between antiretroviral drugs and second-line 
antituberculosis agents. MDR-TB treatment outcomes are 
poor as the cure rate is unacceptably low and the death 
and defaulter rates are high. 
The CD4 counts, viral load, liver function test and renal 
function tests were not included in the TB register. 
Therefore, the study could not assess whether the 
differences in immunological, virological, liver function 
and renal function profile could affect MDR-TB treatment 
outcomes.  
Therefore, studies involving a higher number of 
patients subdivided into groups of patients with similar 
immunological, virological, liver function and renal 
function profile are needed in order to confirm that HIV 
infection and changes have any impact on MDR-TB 
treatment outcomes. Secondly, studies focusing on the 
risk factors for default, failure and death need to be 
undertaken. Thirdly, the MDR-TB programme needs to 
be strengthened considerably and a stronger emphasis 
must be placed on individual patient counseling and 
education. Fourthly, tracking systems should be put in 
place to trace defaulters immediately and address their 
problems. Last but not least, the patient’s family should 
be involved where possible. 
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